

PRESS RELEASE

Annual general shareholder meeting of STRATEC approves increased dividend

Birkenfeld, May 26, 2008

The annual general shareholder meeting held on Wednesday, 21 May 2008 approved all of the agenda items with a large majority.

For the 2007 fiscal year, shareholders will receive a dividend of EUR 0.22 per share (previous year: EUR 0.15). This is a 47% increase over the previous year's dividend.

Further, the annual general meeting of shareholders approved the company's authorization to repurchase treasury shares as well as the authorization to use equity derivatives in connection with the acquisition of treasury shares.

About STRATEC

STRATEC Biomedical Systems AG (<http://www.stratec-biomedical.de>) designs and manufactures fully automated systems for its partners in the fields of clinical diagnostics and biotechnology. These partners market such systems, in general together with their own reagents, to laboratories, blood banks and research institutes around the world. The company develops its products on the basis of its own patented technologies. Shares in the company (ISIN: DE0007289001) are traded in the Prime Standard segment of the Frankfurt Stock Exchange and on other exchanges.

The STRATEC Group consists of the publicly listed parent company STRATEC Biomedical Systems AG and of subsidiaries and second-tier subsidiaries in Germany, the USA, the UK, Switzerland and Romania.

Further information can be obtained from:

STRATEC Biomedical Systems AG

André Loy, Investor Relations

Gewerbestr. 37, 75217 Birkenfeld

Germany

Tel: +49 7082 7916 190

Fax: +49 7082 7916 999

E-mail: ir@strattec-biomedical.de